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1. Introduction 
Human biological diversity involves interindividual variability in morphology, behavior, 
physiology, development, susceptibility to disease and response to stressful stimuli and 
drug therapy (phenotypes). Although the human DNA sequence is 99.9% identical among 
individuals, the variations may greatly affect a person's disease susceptibility. Many 
common diseases, and many individual responses to injury, drugs, and non-pharmacologic 
therapies are genetically complex, characteristically involving an interplay of many genetic 
variations in molecular and biochemical pathways (1).  
The year 2007 marked the publication of adequately powered and successfully replicated 
genome-wide association studies that identified significant genetic contributors to the risk of 
common polygenic disease (e.g., coronary artery disease, MI, types I and II diabetes, atrial 
fibrillation, obesity, asthma, common cancers, rheumatoid arthritis, Crohn’s disease and others) (1). 
Crohn’s disease affects a younger age group, with a peak incidence between 10 and 40 years 
of age. The reported incidence of disease is reported to be 5 to 10 per 100,000/yr (2). Despite 
advances in medical treatment, many patients still require surgery. The mainstay of 
management is medical treatment, usually aminosalicylates and steroids. Other immune-
modifying agents are used in severe disease. This chapter is going to focus on the 
relationship between Crohn’s disease (disease and used drugs) and anesthetic medicine. 
2. What is Crohn’s disease? 
Crohn's disease causes a chronic, nonspecific, transmural inflammation of the intestine that 
found throughout the GI tract, from the oropharynx to the anus. Crohn's disease also 
manifests itself in many extraintestinal symptoms of eyes, skin, and joints. The severity and 
relapsing nature of these symptoms severely affect a patient's quality of life and require 
dependence on long-term medical therapy (3). 
Crohn's disease is incurable, and the natural course of the disease is different for each 
patient. Patients will have episodes of disease exacerbation followed by periods of relative 
or complete remission. In a minority of patients, the disease is unrelenting, depending on 
the location and severity of the disease. The primary treatment of Crohn's disease is medical. 
Although the time course may vary, at least 75% of patients will require surgery after 20 
years with the disease. Surgery is indicated for those who do not respond adequately to 
medical therapy and develop complications during the disease process (3). 
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3. Interaction beetween anti-Crohn’s drugs and anesthetic drugs 
3.1 Aminosalicylates 
Sulfasalazine and mesalamine are the two aminosalicylates used for Crohn's disease. The 
primary antiinflammatory, antipyretic, and analgesic actions of salicylates such as aspirin 
are due to blockade of prostaglandin synthesis by inhibition of the cyclooxygenase 1 and 2 
enzymes. These are effective in maintaining remission in patients with mild-to-moderate 
diseases (4). Studies demonstrate that both mesalamine and sulfasalazine are efficacious at 
inducing and maintaining remission, and are often used as long-term maintenance 
treatments. The improved side effect profile of mesalamine has enabled the use of doses that 
are much higher in amount than doses possible with sulfasalazine. However, a number of 
cases of 5-ASA-induced nephrotoxicity have been reported in patients with inflammatory 
bowel disease (IBD) (5, 6). Several case reports have reported renal impairment in the forms 
of dose-dependent ‘analgesic nephropathy’, inhibition of cyclooxygenases or hypersensitivity 
leading to reversible interstitial nephritis in humans. The incidence of renal impairment in 
patients with IBD treated with 5-ASA is estimated to be one in 100 patients, and interstitial 
nephritis occurs in one in 500 patients (7, 8).  
Mahmud et al, were unable to show nephrotoxicity after six months of mesalamine 
treatment in patients with ulcerative colitis using a low dose of 1.2 g/day (9). Similarly, Van 
Staa et al, were not able to demonstrate a relationship between the dose or type of 5-ASA 
and the incidence of renal disease among 19,025 IBD patients on 5-ASA (10). Based on their 
findings, interstitial nephritis related to 5-ASA use appears to be a rare event. Although 
interstitial nephritis occurs infrequently, renal function can be compromised over time with 
the use of 5-ASA. According to a recent report, de Jong et al, did not find a significant 
change in creatinine clearance (CrCl) over an 11-year interval in 200 patients with Crohn’s 
disease (11). However, the mean duration of treatment with 5-ASA was 8.6 years, much 
shorter than the interval that CrCl was measured. This may reflect why the decline in CrCl 
was reported to be within the expected physiological decline in renal function associated 
with aging. Fortunately, the kidneys have the capacity to regain function after an insult; 
thus, creatinine measurements need to be taken at the onset and end of treatment rather 
than time points outside of the actual treatment interval. Also, no case of interstitial 
nephritis was reported by same author (11). In brief, the time of development of renal 
impairment is variable and may be seen as late as after several years. There is also a risk of 
developing irreversible renal disease if not recognized early, in which discontinuation of 5-
ASA could result in recovery of renal function. Monitoring serum creatinine provides an 
easy and inexpensive way to prevent a detrimental side effect. 
3.2 Corticosteroids 
For patients with exacerbations leading to moderate or severe Crohn's disease, steroids are 
the primary therapy. However, they do not help maintain remission and are detrimental 
when used for long-term treatment. The synthetic analogs of cortisol have been developed 
with the primary goal of maximizing glucocorticoid activity while minimizing 
mineralocorticoid effects and decreasing the adverse effects of high quantities of 
systemically active glucocorticoid. Effects of glucocorticoids that are well documented 
include inhibition of the production of proinflammatory cytokines such as tumor necrosis 
factor alpha (TNF-α) and interleukin-l (IL-l) and chemokines such as IL-8; repression of the 
transcription of the genes for certain enzymes such as inducible nitric oxide synthase, 
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phospholipase A2, and cyclooxygenase 2; and blockade of adhesion molecule expression. 
These molecular actions of glucocorticoids result in a blockade of leukocyte migration and 
function and inhibit the effects of numerous important peptide and lipid-derived mediators 
of inflammation (3). 
Corticosteroids can induce clinical remission in Crohn's disease (60% success rate compared to 
30% placebo response). The side effects of corticosteroids are extensive and include 
osteonecrosis, osteoporosis, cataracts, glaucoma, hyperglycemia, hyperlipidemia, 
hypertension, psychosis, and skin changes (3). 
Corticosteroids and its side effects are important in anesthetic practice. Primarily, anesthetist 
must be aware of the need for corticosteroid replacement not only in patients who have 
primary adrenal insufficiency but also in patients who have adrenal insufficiency resulting 
from long-term corticosteroid therapy. Without adequate knowledge, the anesthetist may 
fail to prepare the patient to withstand the stress of surgery and may open the way for life-
threatening hemodynamic abnormalities that accompany inadequate amounts of 
corticosteroids (12). 
Secondly, its known that a long-term medication with prednisolone resulted in a shorter 
duration of an atracurium-induced neuromuscular block in patients with ulcerative colitis 
or Crohn's disease. The underlying chronic IBD itself did not influence the time course of the 
neuromuscular block. Although the mechanism is not fully understood, several possible 
sites of interaction of steroids with neuromuscular transmission have been suggested: (i) 
glucocorticoids have been shown to possess a direct facilitatory effect on the impulse 
generating end of the motor nerve axon; (ii) corticosteroids act presynaptically stimulating 
synthesis, spontaneous release, and stimulated release of acetylcholine; (iii) however, at 
large concentrations, corticosteroids might possess a post-synaptic depressant effect on 
neuromuscular transmission (13). 
On the other hand, medication with prednisolone was associated with a prolonged onset 
time and attenuated maximum block of rocuronium (14). These data are in contrast to the 
results of the study mentioned in the previous paragraph. The reasons for the differences 
between atracurium and rocuronium might be alterations in drug metabolism mediated by 
the glucocorticoid (14). Alternatively, the presence of chronic IBD itself might influence the 
effect of the neuromuscular blocking drug: in an experimental model of systemic 
inflammation, resistance to atracurium was attributed to increased drug binding to a1-acid 
glycoprotein. Changes in acetylcholine receptor expression in systemic inflammation could 
was not be observed (15). 
A reliable effect of neuromuscular blocking drugs is important to all anaesthesiologists in 
their clinical routine. A delayed recovery from a neuromuscular block might contribute to 
severe complications; even increased mortality could be proved previously (16). However, 
an unexpectedly decreased effect of the drug might also lead to intraoperative complications 
as a result of coughing or sudden movements. Additionally, it might increase laryngeal 
morbidity, i.e. injuries of the vocal cords (17). 
Thirdly; adolescent or child patients, receiving chronic steroid therapy for IBD underwent 
major intestinal surgery, can develop vasodilation during anesthesia (especially induction of 
anesthesia). Systemic hypotension can occur in patients and we can treate them by large 
volumes of intravenous crystalloid solution which cause intraoperative and postoperative 
water retention with resultant hypertension as well as occasional pulmonary edema and 
seizures. Intravenous fluid administration in excess of maintenance requirements and 
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calculated fluid losses should be given with caution to children/adolescent receiving high-
dose steroids who undergo major intestinal surgery. Perioperative fluid retention under 
those circumstances may be treated best with early diuretic administration (18). 
3.3 Antibiotics 
Although antibiotics are not used to treat specific bacterial organisms, they have been found 
to be effective in the treatment of Crohn's disease, especially for the perianal area. 
Metronidazole is the most common agent employed, although ciprofloxacin has also been 
used. By decreasing the amount of bacterial flora in the intestinal lumen, they act to prevent 
the infectious complications of Crohn's disease, such as abscesses and fistulas (3). Clinical 
trials have shown their efficacy in inducing remission (19, 20).  
Although rare, prolonged and high-dose administration of metronidazole may induce 
cerebellar lesions. Increased awareness of this phenomenon is important, as these lesions are 
reversible with discontinuation of this drug (21). Therefore, metronidazole dosages should 
be reduced in patients with liver dysfunction to prevent the accumulation of metronidazole, 
which can lead to CNS dysfunction and peripheral neuropathy (22). 
Knorr et al reported a case of Q-T interval prolongation in a pediatric patient with no known 
risk factors (including hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, starvation etc.) 
for the development of a long Q-T syndrome (LQTS) (23). After 48 hours of ciprofloxacin 
administration, the patient became bradycardic. Antimicrobial therapy was changed to 
ampicillin and ciprofloxacin was discontinued. The patient’s bradycardia persisted for three 
days after the initial detection, and his Q-T prolongation was deemed resolved six days after 
detection; no other cardiac abnormalities have been reported after this day. The patient's Q-
T interval was normalized within seven days of ciprofloxacin discontinuation. The patient 
did not have any further cardiac anomalies.  
The pharmacologic mechanism of drug-induced LQTS is proposed to be via the blockade of 
delayed rectifier potassium channels of the ventricular myocardium during the 
repolarization phase. This blockade prolongs the cardiac action potential and allows early 
afterdepolarization (EAD), which results in the development of a second action potential. 
The second action potential may create a premature ventricular complex on an ECG, and if 
this dysrhythmia becomes self-sustaining, the resulting pattern of EADs reveals itself as a 
“twisting of the points” on the ECG. With the development of dysrhythmia, the patient may 
be asymptomatic or may present with syncope, palpitations, ventricular tachycardia, or 
sudden death (24, 25). Fluoroquinolone-induced Q-T prolongation is most commonly 
associated with gatifloxacin, moxifloxacin, and the withdrawn agents sparifloxacin and 
grepafloxacin (26). This case demonstrated that the use of ciprofloxacin in patients (esp. 
pediatric) should be restricted to situations in which there is no other safe and effective 
alternative to treat the infection. It is important for clinicians to familiarize themselves with 
the drugs that may propagate Q-T prolongation as well as the risk factors that increase the 
probability of developing drug-induced LQTS (23). 
3.4 Immunosuppressive drugs 
As the increasing number of of evidence points to an immunological etiology of IBD, efforts 
have been made to utilize various immunotherapies. The drugs most commonly used are 
azathioprine and its metabolite, 6-mercaptopurine (6-MP), and antimetabolites that inhibit 
DNA synthesis (27). After administration of azathioprine or 6-MP, the 6-thioguanine 
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nucleotides accumulate intracellularly and are believed to mediate the biological actions of 
these drugs (3). 
Despite over 50 years of investigation, the precise molecular basis for the therapeutic effects 
of the purine analogs is not known. However, intracellular accumulation of 6-thioguanine 
nucleotides causes inhibition of the pathways of purine nucleotide metabolism and DNA 
synthesis and repair, resulting in inhibition of cell division and proliferation. It is plausible, 
but not proven, that antiproliferative or functionally inhibitory actions on cells of the 
immune system, such as lymphocytes, underlie the immunosuppressive actions of 
azathioprine and 6-MP (3). Their value was established in a study that showed 67% of 
patients with a clinical response compared to 8% in the placebo group, although the effect 
was delayed by 3 to 6 months. In addition, 75% of patients were able to discontinue or 
reduce their steroid doses (27). A metaanalysis of nine trials revealed that azathioprine and 
6-MP are effective in patients with an active disease, while the adverse side effects 
approached 10% (28). 
Two categories of adverse effects to azathioprine and 6-MP have been described: allergic, 
occurring early during treatment; and dose-related, generally occurring later. Allergy to 
these drugs can manifest as pancreatitis, fever, rash, nausea, diarrhea, and an allergic 
hepatitis. Approximately 50% of the IBD population beginning treatment with azathioprine 
or 6-MP will experience an allergic reaction to the drug, which can be confirmed by 
rechallenge if necessary. Dose-related toxicities of azathioprine or 6-MP include bone 
marrow depression leading to leukopenia (10% cumulative risk), anemia, thrombocytopenia, 
and hepatic toxicity. If severe, leukopenia can potentially cause profound immune 
suppression and thus predispose to opportunistic infections or neoplasms. If leukopenia 
and a serious infection develop in a patient receiving azathioprine or 6-MP, reversal of bone 
marrow suppression is usually possible with granulocyte colony-stimulating factor. 
Decreases in the white blood cell (WBC) or elevations in liver function tests (LFTs) are 
common and generally respond to small dose reductions if needed, without discontinuation. 
The most important criteria for the success of azathioprine and 6-MP include adequate 
dosing and duration of treatment and individual metabolism of these drugs based on 
detectable thiopurine methyltransferase activity (29). Withdrawal of drug has shown a 70% 
relapse rate (28). 
Methotrexate is a folate analog that inhibits purine and pyrimidine synthesis and has been 
shown in a number of trials to be effective in treating Crohn's disease (30). The principal 
biochemical action of methotrexate, and the mechanism that is believed to be responsible for 
the drug's cytotoxic activity, is inhibition of dihydrofolate reductase. It has alternatively 
been proposed that the antiinflammatory action of methotrexate may be mediated by 
inhibition of cytokine release or by increased release of the endogenous antiinflammatory 
autocoid adenosine. Methotrexate may also have effects on activated T lymphocytes, a 
critical part of the inflammatory infiltrate in IBD. However, this drug has significant side 
effects, including hepatotoxicity. and bone marrow suppression, and thus is reserved for 
patients wIth severe Crohn's that is refractory to other therapies (3). 
The latest class of drugs that has resulted in huge advancements in the treatment of Crohn's 
disease are the anti-tumour necrosis factor alpha (TNF-α) agents. Levels of TNF-α are 
increased in Crohn's disease, and in a study of its efficacy, it was noted to produce fistula 
healing (3). Infliximab, a monoclonal antibody against TNF-α, is licensed for the 
management of severe active Crohn’s disease and moderate to severe ulcerative colitis in 
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patients whose condition has not responded adequately to treatment with a corticosteroid 
and a conventional immunosuppressant or who are intolerant of them (31). It has been 
associated with acute demyelination of the central nervous system (32-34). Recently, 
Drummonad at al. reported profound postoperative muscle weakness in a patient who had 
been treated with infliximab (35). However, reports in literature suggesting interactions 
between infliximab and any anaesthetic drugs are unavailable. It is possible that the 
immunosuppressive effect of the hydrocortisone bolus (given at the induction of anesthesia) or 
simply of the surgery itself may have interacted with the infliximab, hastening the onset of 
symptoms. Therefore every patients recently treated with infliximab should have a 
neurological examination documented at pre-operative assessment in order to provide a in 
case should problems occur postoperatively. 
On the other hand; it is well known that infliximab can worsen congestive heart failure. The 
preliminary results of a study assessing the heart function (by means of electro-and 
echocardiogram) during infliximab therapy, in twelve paediatric IBD patients (9 Crohn's 
disease, 3 ulcerative colitis), have been published (36). Seven out of 12 patients showed cardiac 
disturbances consisting of dilation of the cardiac cavities (5 cases) and septal hypertrophy (2 
cases), with a direct correlation between the length of Q–T interval and the systolic and 
diastolic diameter of the left ventricle. These findings point to an increased risk of 
developing arrhythmias in these patients. However, further and more complete studies 
should be done before recommendations about cardiologic work-up required before 
surgery. 
Vitamin B12 (cyanocobalamin) is an integral component of two biochemical reactions in 
humans: the conversion of L-methylmalonyl coenzyme A into succinyl coenzyme A and the 
formation of methionine by methylation of homocysteine. The transmethylation reaction is 
essential to DNA synthesis and to the maintenance of the myelin sheath by the methylation 
of myelin basic protein. Active vitamin B12 contains cobalt in its reduced form (Co+). 
Nitrous oxide produces irreversible oxidation to the Co++ and Co forms that renders 
vitamin B12 inactive. The etiologies of vitamin B12 deficiency include many situations such 
as malabsorption (because of celiac disease, colitis, etc.). Patients with vitamin B12 deficiency 
are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia. If 
unrecognized, the neurologic deterioration becomes irreversible and may result in death 
(37). 
4. Certain circumstances in Crohn's disease which may affect anesthesia 
4.1 Anemia 
Anemia is the most common systemic complication of IBD (38). Anemia in IBD is a 
prototype of a combination of iron deficiency and anemia of inflammation (i.e. anemia of 
chronic disease) which is caused by negative effects of an activated immune system at 
different levels of erythropoiesis. Inflammation affects three major steps essential for normal 
erythropoiesis and can, therefore, lead to the development of anemia of inflammation. These 
effects are: (i) an immunity-driven diversion of iron traffic leading to retention of the metal 
in macrophages and thus to iron-deficient erythropoiesis; (ii) blunting of the biological 
activity of erythropoietin, the major erythropoiesis-stimulating hormone; and (iii) inhibition 
of the differentiation and proliferation of erythroid progenitor cells (39).  
Anemia in IBD can also be induced by deficiency of vitamins, such as cobalamin and folic 
acid, a condition which further impairs the proliferation of hematopoietic progenitor cells 
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(40), or by certain medications, such as thiopurine analogs (6-mercaptopurine, azathioprine), 
sulfasalazine and methotrexate, most of which can inhibit erythropoiesis directly (41). 
The severity of anemia in IBD varies considerably (42). The lower hemoglobin levels below 
which anemia was defined as present were those proposed by the World Health 
Organization (non-pregnant women, 12.0 g/dL; men 13.0 g/dL). Most patients with IBD have 
mild to moderate anemia (hemoglobin above 10.0g/dL), but in the presence of bleeding 
episodes, the hemoglobin concentration may decrease further (41, 43).  
The persistence of anemia is associated with impaired cardiac and renal function, reduced 
systemic oxygen delivery, decreased physical activity, fatigue, and impaired quality of life 
or ability to work (41, 43, 44). However, anemia is a comorbid condition which is associated 
with other diseases (such as transfusion associated hepatitis C) or even death (45).  
Preoperative anemia is a major risk factor for adverse outcome in major surgery and, it’s 
also one of the most important risk factor for perioperative blood transfusions (46). With 
various multivariate statistics and propensity score matching in some studies, the authors 
unanimously found that preoperative anemia and perioperative allogeneic blood 
transfusions (ABT) were both independent risk factors for postoperative mortality, ischemia, 
and infections (47). 
The question of what hemoglobin/hematocrit (Hb/Hct) level justifies the risks associated 
with the administration of blood has been widely discussed. The inviolable “10-30” rule has 
been abandoned. Experience with several patient subpopulations (renal failure, military 
casualties, Jehovah's Witnesses) and systematic study has revealed that considerable greater 
degrees of anemia can be well tolerated and that, in many situations, morbidity and 
mortality rates did not increase until Hb levels fell below 7 g/dL (48, 49). As significant as 
the identification of a 7 g/dL threshold for increased morbidity was the observation that 
stable general medical-surgical managed to a target Hb of 10g/dL fared less well than a 
parallel group managed with a transfusion trigger of 7 g/dL (48). That observation implies 
an adverse effect of transfusion. Accordingly, the contemporary transfusion trigger for 
stable general medical-surgical patients is 21%/7.0 g/dL (Hct/Hb). However, there is 
evidence that the threshold for patients with cardiac disease should be higher (48). That 
evidence includes an investigation supporting a threshold of 30%/10 g/dL (Hct/Hb) in 
patients who have suffered a recent acute myocardial infarction (50), and an observational 
study suggests better outcomes in patients with several cardiac diagnoses (cardiac and 
vascular surgery, ischemic heart disease, dysrhythmias) above a threshold of 9.5g/dL (51). The 
Practice Guidelines for Blood Component Therapy developed by the American Society of 
Anesthesiologists (ASA) state that “red blood cell transfusion is rarely indicated when the 
hemoglobin concentration is greater than 10 g/dL and is almost always indicated when it is less than 
6 g/dL. The indications for autologous transfusion may be more liberal than for allogeneic 
(homologous) transfusion”(52). 
Blood transfusions are widely used as an immediate intervention for rapid correction of 
severe or life-threatening anemia. However, such transfusions do not correct the underlying 
pathology and do not have a lasting effect. The decision on whether to administer blood 
should not, therefore, be based only on the hemoglobin level, but should also take clinical 
symptoms and co-morbidity into account. Whether blood transfusions affect immune 
function and whether they are cause-effectively linked to mortality in patients undergoing 
surgery (46) or being treated in intensive care units remains controversial (53). 
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The clinician's responsibility is to anticipate, on a patient-by-patient basis, the minimum Hb 
level (probably in the range of 7 to 10 g/dL) that will avoid organ damage due to oxygen 
deprivation. Determining this individual “transfusion trigger” requires reference to the many 
elements of patient condition that determine demand for the delivery of oxygen and the 
physiologic reserve (54), including ongoing blood loss and the potential for sudden blood 
loss. Ultimately, the decision to transfuse red blood cells (RBCs) should be made on the basis 
of the clinical judgment that the oxygen-carrying capacity of the blood must be increased to 
prevent oxygen consumption from outstripping oxygen delivery. That judgment is based on 
an understanding of the physiologic mechanisms that compensate for anemia and the limits 
of those mechanisms. 
4.2 Respiratory problems 
The pathogenesis of IBD-associated respiratory lesions is unknown. The inflammatory 
lesions seen beneath the bronchial epithelium are similar to those observed beneath the 
colonic epithelium in IBD. Both epithelia have columnar structures and mucosal glands, and 
both sites are challenged constantly by foreign antigens. There are two possible hypotheses: 
(i) a systemic immunologically-mediated phenomenon originating from the intestinal 
inflammatory process underlies the bronchial/parenchymal changes in the lungs; or (ii)  a 
defect in the regulation of local immune response which is evident in both gastrointestinal 
and respiratory tract in response to as yet unknown antigens (55).  
While clinically apparent bronchopulmonary disease complicating IBD is rare, the function 
of the small airways and the diffusion capacity of the lungs has been shown to be affected in 
IBD patients without any clinical respiratory involvement (56, 57). Heatley et al. Reported 
reduced diffusion capacity for carbon monoxide in 25%, and spirometric abnormalities in 
50%, of 102 patients with IBD (58). Adenis et al., using clearance of 99mTechnitium isotopic 
DTPA, suggested that patients with Crohn’s disease may have increased pulmonary 
vascular permeability due to latent alveolitis (57). 
Respiratory symptoms can occur at any time in the history of IBD. Most interstitial lung 
diseases associated with IBD start gradually with weeks or months of breathlessness 
associated with cough. Bronchiolitis can progress unrecognised as there is no distinctive 
pattern of physical signs (59). Despite exertional dyspnoea, there may be no audible signs on 
auscultation. Radiological signs are also variable. Chest radiographs may show diffuse or 
patchy infiltrates but can be normal. Computed tomography scan is more helpful in 
demonstrating diffuse nodular or ground glass opacities which maybe patchy or uniform 
(60). Pulmonary function tests usually show a restrictive defect in interstitial lung 
involvement with reduced gas transfer and resting/exercise hypoxaemia. Broncho-alveolar 
lavage, useful in ruling out infectious causes, generally shows lymphocytosis. A lung biopsy 
is usually necessary to confirm the diagnosis and may aid in indicating prognosis (61) 
Drug-induced interstitial lung disease has been well-reported in IBD, with clinical features 
very similar to IBD-associated interstitial lung diseases. Most cases have been attributed to 
salicylates and mesalazine therapy (62).  Salicylates (sulphasalazine and 5-ASA) can induce 
different lung diseases such as bronchiolitis obliterans, bronchiolitis obliterans with 
organising pneumonia (BOOP), and interstitial pneumonitis with the most common being 
eosinophilic pneumonitis. 
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Drug-induced lung disease can be confirmed by drug rechallenge and improvement has 
occurred following drug withdrawal. Generally, prognosis is favourable in the majority of 
salicylate-induced interstitial lung diseases, but fatal outcomes due to irreversible lung 
fibrosis and rapidly progressive interstitial lung disease have been described (63). 
Hypersensitivity pneumonitis may occur with methotrexate. This is a serious complication, 
occasionally fatal, with a reported prevalence of 3.1 to 11.6% in patients receiving long-term 
low-dose therapy (64, 65). The clinical features include dyspnoea, fever and cough with 
diffuse alveolar and interstitial shadowing on chest X-ray. Treatment requires the 
immediate withdrawal of methotrexate and high dose corticosteroids. A few cases of 
azathioprine-induced interstitial lung diseases have been reported in non-IBD patients. 
Opportunistic infections have been described in patients treated with immunosuppressants, 
particularly cyclosporin, and most recently, infliximab (66, 67). 
Most respiratory disease associated with IBD responds well to corticosteroids with the 
exception of constrictive bronchiolitis obliterans (68). But, in some patients, pathological 
changes such as bronchiectasis and bronchiolitis obliterans are irreversible. Initial treatment 
of airways inflammation is with inhaled corticosteroids. Systemic corticosteroids are used to 
treat parenchymal disease (BOOP, interstitial pneumonitis and necrotic nodules). Methotrexate 
or salicylates should be withdrawn as potential causes of interstitial lung disease. The 
duration and dosage of corticosteroid treatment should be guided by symptomatic response 
and pulmonary function tests. In the case of BOOP, the duration of corticosteroid treatment 
is usually six months and clinical improvement can be seen within days to weeks (69). 
4.3 Renal problems 
Secondary amyloidosis (SA) is a rare but serious complication of IBD, generally seen in 
Crohn's disease. Indeed SA is frequently described as a major cause of death in patients with 
Crohn’s disease (70). At least 1% of patients with Crohn's disease develop SA. In literature, 
the time lapse between the onset of Crohn's disease and the diagnosis of SA has been 
reported to range from one to 21 years. In most patients, protein-uria heralded the onset of 
renal involvement from amyloid and occurred from three to 15 years after Crohn's disease 
diagnosis (71). Renal failure is the most common clinical presentation of SA, ranging from 
nephrotic syndrome and impaired renal function–to renal failure, with a potential for high 
morbidity (72).   
So far no effective treatment for SA has been identified. Multiple therapeutic strategies have 
been employed with discouraging results, including colchicine and immunosuppressive 
drugs such as tumor necrosis factor alpha inhibitors The therapeutic approach to these 
patients should be dual. On the one hand it aims at minimizing the activity of the 
underlying disease in order to mitigate or prevent serum amyloid A (SAA) production, the 
precursor of plasma amyloid that is deposited in tissues and will be responsible for their 
malfunction. On the other hand it is aimed at treating the disease once it is established. The 
treatment of SA has two pillars: a) improvement of renal dysfunction; and b) reduction of 
inflammation, the constant source of SAA, thus trying to prevent the formation of amyloid, 
and hence curb the progression of disease (73, 74). Dialysis and renal transplantation are 
reserved for patients with end-stage renal failure. Survival rates for these patients have 
improved in recent years with the introduction of these drugs, but there is still no 
standardized treatment, and prognosis remains dismal (75). 
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4.4 Pain problems 
Pain is a common component of IBD, especially during acute inflammatory episodes. The 
substances involved in visceral hyperalgesia are present throughout the gastrointestinal 
tract and their synthesis is increased during acute clinical episodes of IBD (76-79). On the 
other hand, opioid-binding proteins are involved as acutephase reactants and their 
concentrations are elevated in IBD (80), and the modulation of pain during this disease is 
therefore unclear.  
However, medical management of IBD remains challenging and cannot always control all 
aspects of the disease. Even with therapy, patients frequently suffer not only from diarrhea 
and rectal bleeding but also from abdominal pain, cramps and arthralgia. Although the 
established disease activity indices only include abdominal pain as one variable, pain occurs 
throughout the body with pain attacks severely diminishing the patient’s health-related 
quality of life (HRQOL) and interfering with their social and occupational habits. 
Localization of pain is a matter of great interest because of the different treatment options 
for abdominal pain and arthralgia. While the treatment of arthralgia could be composed of 
physical therapy, steroids or sulfasalazine, abdominal pain requires a more effective anti-
inflammatory therapy. In cases of persistent pain despite remission, IBS-like symptoms, 
depression or drug-related side effects must also be considered (81). 
The use of analgesics and their dosage is difficult to gauge and should be well evaluated. 
Pain killers have a variety of known effects and side effects. Given the gastrointestinal side 
effects and the possibility of aggravating mucosal inflammation, non-steroidal anti-
inflammatory drugs (NSAID) should be avoided in IBD. However, opioids might also 
worsen pain in IBD patients because long-term use of opioids may also be associated with 
the development of abnormal sensitivity to pain and a progressive decline in plasma cortisol 
levels (82). Consequently, Smith and coworkers recently showed that treatment with low-
dose naltrexone improved disease course and HRQOL of Crohn’s disease (83). An 
alternative explanation for the discrepancy between use of analgesics and perception of pain 
might be the high prevalence of functional somatic symptoms (IBS-like symptoms) among 
IBD patients (84). 
Previous studies have demonstrated an increase in opioid requirements and a large 
variability in patients with Crohn’s disease or ulcerative colitis compared with controls 
undergoing abdominal major surgery. Two recent studies have indicated the existence of 
diffuse hyperalgesia during an intestinal inflammatory process (85, 86). Verne and 
colleagues confirmed that patients with functional bowel disorder have visceral cutaneous 
hyperalgesia that are distributed over a considerable rostro-caudal distance but are yet 
optimally expressed in lumbosacral dermatoma (87). Also, that study demonstrate that the 
inflammatory status seems to influence opioid requirements during surgery for IBD. 
Inflammation induces visceral and cutaneous hyperalgesia that may explain the decrease in 
opioid requirements in patients with quiescent IBD compared with those who have an 
active IBD. On the other hand, during surgery, pain stimulation was much more related to 
painful stimuli to the abdominal wall than to direct stimuli to the inflammatory bowel. 
Hence, we may speculate that increased opioid requirements during abdominal wall 
stimulation are linked to this somatic hyperalgesia in lumbosacral referred dermatoma. 
However, the decrease in opioid consumption may also be related to changes in 
pharmacokinetic factors due to the inflammation (88). 
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5. Conclusion 
We are faced with the Crohn’s disease in practice of anesthesia. We usually pay attention to 
the type of surgery. However, our patients's clinical status (nutrition, blood protein level, etc.), 
interactions between anesthetic drugs and patient used drugs are impotant too. Thus we can 
help prevent complications, early discern to negative signals and start effective treatments.  
Nothing is simple, nothing is resolved. 
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